Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606632 · ClinicalTrials.gov registry record · Phase 3
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
A Phase 3 study, sponsored by Heidelberg Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT00606632: Completed Phase 3 study, sponsored by Heidelberg Pharma.
NCT00606632 is a Phase 3 study that has completed, run by Heidelberg Pharma. The registered enrollment target is 226 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606632, a Phase 3 study, has completed, sponsored by Heidelberg Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
Interventions
- DRUG 124-Iodine-cG250 (124I-cG250)
- PROCEDURE CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606632
The ClinicalTrials.gov registry entry for NCT00606632 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heidelberg Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 124-Iodine-cG250 (124I-cG250) is the first listed.
NCT00606632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606632 about?
NCT00606632 is a clinical study titled "Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody". This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
What is the current status of trial NCT00606632?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2008-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00606632?
The interventions under investigation include: 124-Iodine-cG250 (124I-cG250) (DRUG), CT (PROCEDURE).
Who is sponsoring clinical trial NCT00606632?
This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.